Evotec AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
March 14, 2018 at 01:20 pm EDT
Share
DGAP Preliminary announcement financial reports: Evotec AG / Preliminary announcement on the disclosure of financial statements
Evotec AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
14.03.2018 / 18:16
Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Evotec AG hereby announces that the following financial reports shall be
disclosed :
Report: Annual financial report
Date of disclosure / German: March 28, 2018
Date of disclosure / English: March 28, 2018
German: https://www.evotec.com/finanzberichte
English: https://www.evotec.com/financial-reports
Report: Annual financial report of the group
Date of disclosure / German: March 28, 2018
Date of disclosure / English: March 28, 2018
German: https://www.evotec.com/finanzberichte
English: https://www.evotec.com/financial-reports
Report: Financial report of the group (half-year/Q2)
Date of disclosure / German: August 09, 2018
Date of disclosure / English: August 09, 2018
German: https://www.evotec.com/finanzberichte
English: https://www.evotec.com/financial-reports
14.03.2018 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, womenâs health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Evotec AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EVOTEC SE 
